Calypso Biotech’s portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints involved in multiple immune pathologies.
Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK but also has recently emerged as a…

Calypso Biotech’s portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints involved in multiple immune pathologies.

Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK but also has recently emerged as a key driver of disease-perpetuating tissue resident memory T cells (TRM). Thus, CALY-002 has the potential to be a game-changing treatment in multiple indications where TRM cells are important.

Calypso Biotech targets diseases which incidence has dramatically increased in recent years due to changes in diet and lifestyle, likely through alteration of the microbiome. Among these, Eosinophilic Esophagitis (EoE) is an emerging immune pathology driven by food antigens and resulting in severe dysphagia and poor quality of life in children and adults. Therapeutic options for EoE are very limited, and Calypso Biotech has demonstrated the strong potential of its anti-IL-15 CALY-002 antibody for EoE. CALY-002 has obtained Orphan Drug Designation status for EoE with the European Medicines Agency.

Calypso Biotech is headquartered in Amsterdam (The Netherlands), and has offices and laboratories in Geneva (Switzerland). Calypso Biotech is also a resident company of Johnson & Johnson Innovation JLABS at Beerse in Belgium (JLABS@BE).

Calypso Biotech’s portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints involved in multiple immune pathologies.
Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK but also has recently emerged as a…

Calypso Biotech’s portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints involved in multiple immune pathologies.

Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK but also has recently emerged as a key driver of disease-perpetuating tissue resident memory T cells (TRM). Thus, CALY-002 has the potential to be a game-changing treatment in multiple indications where TRM cells are important.

Calypso Biotech targets diseases which incidence has dramatically increased in recent years due to changes in diet and lifestyle, likely through alteration of the microbiome. Among these, Eosinophilic Esophagitis (EoE) is an emerging immune pathology driven by food antigens and resulting in severe dysphagia and poor quality of life in children and adults. Therapeutic options for EoE are very limited, and Calypso Biotech has demonstrated the strong potential of its anti-IL-15 CALY-002 antibody for EoE. CALY-002 has obtained Orphan Drug Designation status for EoE with the European Medicines Agency.

Calypso Biotech is headquartered in Amsterdam (The Netherlands), and has offices and laboratories in Geneva (Switzerland). Calypso Biotech is also a resident company of Johnson & Johnson Innovation JLABS at Beerse in Belgium (JLABS@BE).